Abstract
Preclinical models and data from clinical trials suggest that cancer is a preventable disease. However, demonstration of a preventive effect requires large phase III clinical trials of long duration and involves many thousands of participants. The decision to proceed with phase III studies therefore must be informed by robust efficacy and safety data. This requires a systematic review of all available preclinical, epidemiological, and clinical data, along with a mechanistic understanding of the biology of the disease under study. In this review we identify the issues that are critical to decision-making prior to embarking on late phase prevention clinical trials and provide a framework for making such decisions.
Keywords: cancer, chemoprevention, clinical trials, carcinogenesis, efficacy, EGFR, safety, oncologic, phase III trials, NSAID
Current Drug Targets
Title: Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Volume: 12 Issue: 13
Author(s): Ronan J. Kelly, Ariel Lopez-Chavez and Eva Szabo
Affiliation:
Keywords: cancer, chemoprevention, clinical trials, carcinogenesis, efficacy, EGFR, safety, oncologic, phase III trials, NSAID
Abstract: Preclinical models and data from clinical trials suggest that cancer is a preventable disease. However, demonstration of a preventive effect requires large phase III clinical trials of long duration and involves many thousands of participants. The decision to proceed with phase III studies therefore must be informed by robust efficacy and safety data. This requires a systematic review of all available preclinical, epidemiological, and clinical data, along with a mechanistic understanding of the biology of the disease under study. In this review we identify the issues that are critical to decision-making prior to embarking on late phase prevention clinical trials and provide a framework for making such decisions.
Export Options
About this article
Cite this article as:
J. Kelly Ronan, Lopez-Chavez Ariel and Szabo Eva, Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials, Current Drug Targets 2011; 12 (13) . https://dx.doi.org/10.2174/138945011798184173
DOI https://dx.doi.org/10.2174/138945011798184173 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics Nephrotoxicity of Bisphenol A (BPA) -An Updated Review
Current Molecular Pharmacology Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets Novel Function of Beta 2 Glycoprotein I in Angiogenesis
Current Angiogenesis (Discontinued) Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets Highlights on Medical Treatment of Uterine Fibroids
Current Pharmaceutical Design Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Arsenic Trioxide Exerts Anti-lung Cancer Activity by Inhibiting Angiogenesis
Current Cancer Drug Targets Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Somatostatin and its Analogs
Current Drug Targets Pregnancy and Postpartum Influences on Rheumatoid Arthritis Activity:Natures Model to Investigate Systemic Biological Mechanisms in the Disease
Current Rheumatology Reviews Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Signal Transduction Targets in Prostate Cancer
Current Signal Transduction Therapy Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Topics in Medicinal Chemistry Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers
Anti-Cancer Agents in Medicinal Chemistry Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology